The aim of this study was to evaluate the sensitivity and the levels of 1,3-b-D-glucan (BDG) among patients with candidaemia due to different Candida species. Retrospective study of all patients who had a single-species candidaemia and BDG testing performed within 48 h from the onset of candidaemia during 2009e2015 was performed. Factors influencing the sensitivity of BDG, including the presence of a central venous catheter, antifungal therapy and Candida species, were analysed in univariate and multivariate models. In all, 107 patients with the following Candida distribution were included: 46 (43%) Candida albicans, 37 (35%) Candida parapsilosis, and 24 (22%) other species. BDG sensitivity and levels were the highest in C. albicans candidaemia and lowest for C. parapsilosis (respectively, 72% and 410 pg/ mL for C. albicans, 41% and 39 pg/mL for C. parapsilosis, and 63% and 149 pg/mL for other species; p 0.015 and p 0.003). In multivariate analysis, Candida species (parapsilosis versus others) was the only factor influencing the sensitivity of BDG (OR 0.3, 95% CI 0.1e0.7, p 0.006). The sensitivity of BDG in candidaemia seems highly dependent on the fungal species, with the lowest being for C. parapsilosis. M. Mikulska, CMI 2016;▪:1
(1,3)-b-D-Glucan (BDG) is a useful serological marker of invasive fungal infections, and it is recommended by international guidelines for the diagnosis of invasive candidiasis [1] . Although all Candida species contain BDG within the fungal cell wall, some species may have lower concentrations than others. For example, an in vitro study reported lower levels of BDG in non-albicans species such as Candida lusitaniae when compared with other species [2] . In addition, two studies with a low number of Candida parapsilosis isolates suggested a lower sensitivity of BDG in the case of C. parapsilosis candidaemia compared with infections caused by other species [3e5] .
Candida parapsilosis is being isolated with increasing frequency and is currently the second or third most frequent species isolated in patients with candidaemia [6, 7] . Therefore, understanding the performance of BDG in this infection is of utmost importance. The aim of this study was to evaluate the differences in the sensitivity of BDG and in BDG levels among patients with candidaemia caused by different Candida species, with particular attention to candidaemia due to C. parapsilosis.
All patients who had a single-species candidaemia between 1 January 2009 and 30 June 2015 and sampling for BDG testing performed within (before or after) 48 h from the onset of candidaemia were included in the study. The onset of candidaemia was defined as the day on which the first blood culture, which later resulted positive for Candida, was drawn. The patients were retrospectively identified by cross-checking the central laboratory database of all cases of candidaemia and the database of BDG testing.
The following demographic and clinical data were collected: age, gender, baseline co-morbidities (chronic renal failure, diabetes mellitus, solid or haematological malignancy), haematopoietic stem-cell transplantation, recent major surgery or chemotherapy (within 3 months), ward of stay at the time of candidaemia (intensive care unit/surgical versus haematological/medical), Candida colonization of non-sterile sites, presence of a central venous catheter, haemodialysis, receipt of albumin or immunoglobulins, antifungal prophylaxis, serum BDG values, timing of the BDG test with respect to the positive blood culture and the initiation of antifungal therapy, type of Candida spp. responsible for candidaemia.
Informed consent for the use of anonymized clinical data for scientific purposes was obtained for every admitted patient, in line with the standard practice in our centre. For this noninvestigational, retrospective study, the collection of relevant data was performed by the investigators directly involved in patient care using current techniques of ensuring privacy; for this reason, ethics committee approval was not required.
Blood samples were cultured following standard recommendations by the automated BacTEC method with both aerobic and anaerobic media (Bactec FX; Becton-Dickinson Microbiology Systems, Franklin Lakes, NJ, USA). Identification of Candida spp. was performed by the VITEK 2 automated system (bioM erieux, Marcy l'Etoile, France).
Evaluation of BDG was performed with the Fungitell assay (Associates of Cape Cod, Cape Cod, MA, USA). All samples were stored at À20 C, and assays were performed according to the manufacturer's recommendations. BDG values !80 pg/mL were considered positive according to the manufacturer's indications, with detection limits of <7 pg/mL and >523 pg/mL. For comparison of BDG values, samples testing <7 pg/mL or >523 pg/mL were considered, respectively, as 7 and 523 pg/mL. Values of BDG were reported as median with interquartile range (IQR) and were compared between patients with C. albicans, C. parapsilosis or non-albicans non-parapsilosis candidaemia as continuous variables, by means of ManneWhitney or KruskaleWallis tests, if applicable; p value was reported two-tailed and considered significant if 0.05.
Finally, the aforementioned demographic and clinical characteristics of patients were compared between patients with a positive or negative BDG test by means of the chi-square test or the two-tailed Fisher exact test, as appropriate. To assess the independent role of variables, a stepwise backward multivariate logistic model was fitted to the data, considering all variables that had shown an association (p <0.20) with a positive BDG test in the univariate analysis.
During the study, 755 patients developed single-species candidaemia and 107 had BDG testing performed within 48 h from the onset of candidaemia (14%). Of note, such an appropriate use of BDG has significantly increased over the study years, from 6% of cases in 2009 to 48% in 2015 (p <0.0001).
Among 107 patients included in the study, the majority were male (58%), with a median age of 68 years (IQR 54e80). The distribution of Candida species was as follows: 43% C. albicans (n ¼ 46), 35% C. parapsilosis (n ¼ 37), and 22% other species (n ¼ 24), including Candida glabrata (n ¼ 10), Candida tropicalis (n ¼ 7), Candida krusei (n ¼ 4) and Candida kefyr, Candida guilliermondii and Candida lusitaniae (n ¼ 1 each). Demographic and clinical characteristics of patients are reported in the first column of Table 1 . Among demographic and clinical variables, C. parapsilosis was significantly more frequent among patients with recent chemotherapy (30% versus 9%, p 0.004), whereas there were no statistically significant differences in age, gender, ward of admission, comorbidities, colonization, presence of central venous catheter or antifungal prophylaxis or therapy.
The sensitivity of BDG for the diagnosis of candidaemia was 59% (positive in 63 among 107 patients) and the median BDG value was 158 pg/mL (IQR 26e523). Significant differences in the sensitivity and in median BDG levels existed according to the different Candida species (for the purpose of this study, infections caused by non-albicans and non-parapsilosis isolates were grouped together, because of small numbers of singular species not allowing for separate analyses). Sensitivity was 72% for C. albicans, 41% for C. parapsilosis and 63% for other species (33/46, 15/37 and 15/24, respectively, p 0.015), whereas the respective median serum BDG concentrations were 410 pg/mL (IQR 74e523), 39 pg/mL (IQR 7e499) and 149 pg/mL (IQR 53e523), p 0.003, as shown in Fig. 1 . Sensitivity and median serum BDG levels were compared between C. albicans and all non-albicans candidaemia. They were higher for C. albicans compared with non-albicans candidaemia (respectively, 72% versus 49%, p 0.02; and 410 pg/mL versus 72 pg/mL, p 0.004), and the differences were driven by particularly low sensitivity and BDG levels in candidaemias due to C. parapsilosis. In fact, they were lower for C. parapsilosis compared with all other species (respectively, sensitivity 41% versus 65%, p 0.005; median BDG 39 pg/mL versus 244 pg/mL, p <0.001), whereas no statistically significant difference was observed when comparing C. albicans infections with the nonalbicans and non-parapsilosis group (p 0.4 for sensitivity and p 0.2 for median values).
The results of univariate and multivariate analyses of factors associated with positivity of the BDG test are reported in Table 1 . As shown in the table, no factors other than the species of Candida appreciably influenced the sensitivity of the test, with the association between C. parapsilosis and negative BDG being retained in the final multivariate model (OR 0.3, 95% CI 0.3e0.7, p 0.006).
In conclusion, the results of this study of 107 cases of candidaemia, one-third of which were infections caused by C. parapsilosis, demonstrated that the performance of BDG in candidaemia appears to be highly dependent on the fungal species, the highest sensitivity being observed in C. albicans and the lowest in C. parapsilosis candidaemia. The 72% sensitivity of BDG for C. albicans in the current study is consistent with the performance reported in the 2012 European guidelines (>65%) [8] , and the overall low sensitivity BDG was conceivably due to the high proportion of C. parapsilosis in our cohort.
Our data confirm the findings from two previous reports from smaller groups of patients, these suggested lower sensitivity observed in C. parapsilosis candidaemia with respect to candidaemia caused by other species [3, 4] . In the first study, among 92 patients with invasive candidiasis, including 18 cases caused by C. parapsilosis, the sensitivity of BDG at the standard cut-off of 80 pg/mL was 81% for C. albicans and 61% for C. parapsilosis [4] . In the second one, our group reported a similar difference in sensitivity: 81% in patients with C. albicans infection versus 65% in 17 patients with C. parapsilosis candidaemia. Although neither of the two previous reports analysed the difference in median BDG values among the species, this study actually found significantly lower levels of BDG in patients with infection caused by C. parapsilosis.
One of the limitations of the current study is the fact that all the BDG concentrations above the upper limit of the assay detection were reported as 523 pg/mL. However, this might only contribute to an under-estimation of the differences in BDG values among Candida species because 48% of patients with C. albicans had BDG values above the upper limit of detection, compared with only 24% of patients with C. parapsilosis candidaemia, and 38% of those with infection caused by the other species (data not shown).
Therefore, the results of this study showed that the performance of BDG is significantly influenced by Candida species, and may result in poor diagnostic performance in settings where C. parapsilosis is frequent.
